|
|
New Data on Imitrex(R) Indicates Reduction in Migraine-Related Medical Claims In Managed Care Organization.
- Article from:
-
PR Newswire
- Article date:
-
June 29, 1999
|
Copyright informationCOPYRIGHT 1999 PR Newswire Association, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO, June 29 /PRNewswire/ -- Patients who used Imitrex(R) (sumatriptan succinate) Injection or Tablets required fewer migraine-related primary-care physician office visits, emergency department visits and medical procedures in the six-month period after they began taking Imitrex, according to data presented at a Measuring and Managing Migraine and Disabling Headache symposium held last week in San Francisco. Researchers say this new data demonstrates that the use of Imitrex may result in a reduction in migraine-related medical claims in a managed care setting. The health-care costs of migraine-related treatment can be high for managed care organizations.
The ...